Discover how IFLI's journey from Inception to Innovation in Follicular Lymphoma Research and Treatment is transforming patient care and outcomes
Founded in February 2022, IFLI is a non-profit organization dedicated to advancing Follicular Lymphoma (FL) research and treatment. We are committed to establishing strong partnerships that enhance our understanding of FL biology and significantly impact treatment options available to patients.
.png)
Fund the best initiatives worldwide by building strong partnerships and maximizing available resources, aiming to transform Follicular Lymphoma research
Accelerate the development of innovative treatment options to extend the life expectancy of people with follicular lymphoma and ultimately develop a cure
Effectively prioritize tasks based on organization mission and goals
Show respect to others and confronts interpersonal issues directly
Prioritize resolution of partnership issues effectively
Respond promptly and honor commitments to internal and external stakeholders
Innovate and Act! Take initiative. Press hard and swiftly for progress, take risks and don’t be afraid to challenge the norms or to fail
Make recommendations to continuously improve methods, processes, and systems
Demonstrate adaptability by reacting appropriately to unexpected changes in situations or circumstances
Increase performance through greater efficiency
Seek to develop technical knowledge through learning from other experts
Understand organizational impact of individual decisions and actions
Seek solutions rather than placing blame
Tackle challenges with a sense of purpose, urgency, and determination because the disease won’t wait
Consistently look for ways to improve oneself through growth and development opportunities
Communicate clearly and promptly up, down, and across
Communicate effectively to manage expectations
IFLI is dedicated to supporting advances in understanding the biology of follicular lymphoma patients who are at high risk of progression, and accelerating the development of precision medicine to extend the median life expectancy of FL patients with early progression to ultimately develop a cure for FL.
Capital Allocations
Sponsored Agreements
Program Investments
Venture Philanthropy
Filter by:
Chief Medical Officer
IFLI
NJ, USA
.jpg){kind=avatar}
Director, Portfolio & Project Management
IFLI
CA, USA
Venture Partner
IFLI
CA, USA
Scientific Development Director
IFLI
CA, USA
Business Dev & Licensing Advisor
IFLI
NC, USA
Chairman of Development, Independent Director, Board of Directors
Centessa Pharmaceuticals, Sanofi
MA, USA
Research Director, Director
CIML Marseille, CALYM Carnot Institute
France
Professor of Medicine, Division of Oncology, Siteman Cancer Center
Washington University in St. Louis School of Medicine
MO, USA
Professor of Medicine, Clinical Oncologist
Stanford University
CA, USA
Professor of Hematology/Oncology
Weill Cornell Medical College
NY, USA
Head of Cancer Lymphoid Research
University of British Columbia
Canada
Assistant Professor, Director, Translational and Laboratory Research, Department of Lymphoma - Myeloma, Division of Cancer Medicine
MD Anderson Cancer Center
TX, USA
Assistant Professor of Pharmacology
Weill Cornell Medical College
NY, USA
Design personalized approaches to improve FL patient outcomes
Identify FL patients at high risk of progression and develop the right treatment
Promote data sharing as a catalyst of medical breakthrough
Develop & lead complementary integrated programs
Play an instrumental role in the development of research objectives
Generate metrics and tools to monitor progress and accountability
Develop a diverse portfolio with funds distributed across stages
Combine existing therapies and new technologies
Thank you for your interest in contacting us. Please fill out the form with your inquiry or feedback, and our team will promptly respond to assist you.
